---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078142"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:27:23.975594+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027

## Summary
- Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.
- Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.
- R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.
- Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.
- Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025).

## SEC filing metadata
- accession: 0001104659-25-078142
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/0001104659-25-078142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/tm2522624d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078142
- JSON: https://secwatch.observer/filing/0001104659-25-078142.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.